Loading
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Previous close
$2.435
−$0.175 · -6.70%
After-hours
$2.47
+$0.035 · +1.44%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Day range
Current $2.435
52-week range
Current $2.435
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
8
Overpriced
Sentiment
54
Mixed
Risk
63
High Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Day range
Current $2.435
52-week range
Current $2.435
Operating income
Net income
| Metric (USD) | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Cost of goods sold | 129.09K USD | — | — | — | 391.42K USD |
| Gross profit | −129.09K USD | — | — | — | −391.42K USD |
| Research and development | 537.43K USD | 2.71M USD | 4.17M USD | 8.37M USD | 15.54M USD |
| Selling, general, and administrative | 17.88M USD | 24.56M USD | 15.32M USD | 14.33M USD | 7.47M USD |
| Operating expenses | 18.42M USD | 81.64M USD | 38.56M USD | 116.08M USD | 23.01M USD |
| Interest income | 116.35K USD | — | — | 122.04K USD | 13.18K USD |
| Interest expense | 725.68K USD | 2.43M USD | 706.96K USD | 372.84K USD | 379.61K USD |
| Depreciation and amortization | 129.1K USD | 121.86K USD | 113.5K USD | 123.59K USD | 391.42K USD |
| Operating income | −18.55M USD | −81.64M USD | −38.56M USD | −116.08M USD | −23.4M USD |
| Net income | −178.01M USD | −88.43M USD | −39.68M USD | −113.43M USD | −26.72M USD |
Company facts updated Sep 11, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 22, 2026 | 1:8 | — | — |
Effective May 22, 2026
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
